Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Simplify Asset Management Inc.

Simplify Asset Management Inc. reduced its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 34.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,268 shares of the biopharmaceutical company's stock after selling 10,615 shares during the period. Simplify Asset Management Inc.'s holdings in Intra-Cellular Therapies were worth $1,693,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Wasatch Advisors LP lifted its stake in shares of Intra-Cellular Therapies by 3.5% during the third quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock valued at $281,601,000 after buying an additional 130,351 shares during the period. Bellevue Group AG raised its holdings in Intra-Cellular Therapies by 0.6% in the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company's stock valued at $181,873,000 after acquiring an additional 14,342 shares during the last quarter. State Street Corp lifted its stake in shares of Intra-Cellular Therapies by 3.1% during the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after purchasing an additional 56,664 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock worth $129,463,000 after purchasing an additional 155,655 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Intra-Cellular Therapies by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,708,301 shares of the biopharmaceutical company's stock valued at $125,029,000 after purchasing an additional 22,128 shares during the period. 92.33% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Intra-Cellular Therapies Price Performance

NASDAQ ITCI traded up $0.06 during trading hours on Thursday, hitting $131.75. The company had a trading volume of 1,866,089 shares, compared to its average volume of 1,346,632. The firm's 50 day moving average is $129.00 and its 200 day moving average is $99.05. The company has a market capitalization of $14.01 billion, a price-to-earnings ratio of -151.44 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a fifty-two week low of $64.09 and a fifty-two week high of $131.83.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analyst Ratings Changes

ITCI has been the topic of several recent analyst reports. Piper Sandler reiterated a "neutral" rating and set a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Mizuho downgraded shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $140.00 to $132.00 in a report on Monday, February 24th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Baird R W lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.